Differential modulation of p38 mitogen activated protein kinase and STAT3 signalling pathways by infliximab and etanercept in intestinal T cells from patients with Crohn's disease.
Rosenstiel
P
P
Agnholt
J
J
Kelsen
J
J
Medici
V
V
Waetzig
G H
GH
Seegert
D
D
Schreiber
S
S
D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D003424:Crohn Disease / Q000188:drug therapy*; D000068800:Etanercept; D006801:Humans; D018928:Immunity, Mucosal / Q000187:drug effects; D007074:Immunoglobulin G / Q000494:pharmacology*; D000069285:Infliximab; D007413:Intestinal Mucosa / Q000276:immunology; D018124:Receptors, Tumor Necrosis Factor; D015398:Signal Transduction / Q000187:drug effects; D016176:T-Lymphocyte Subsets / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000068800:Etanercept